Contrarius Investment Management LTD Decreased Buckle (BKE) Holding; Jpmorgan Chase & Company Has Boosted By $1.68 Million Its Chemocentryx (CCXI) Holding – The FinReviewer

The Buckle, Inc. (NYSE:BKE) Logo

Contrarius Investment Management Ltd decreased Buckle Inc (BKE) stake by 4.39% reported in 2018Q2 SEC filing. Contrarius Investment Management Ltd sold 14,629 shares as Buckle Inc (BKE)’s stock declined 17.15%. The Contrarius Investment Management Ltd holds 318,264 shares with $8.56M value, down from 332,893 last quarter. Buckle Inc now has $897.46M valuation. The stock decreased 5.02% or $0.98 during the last trading session, reaching $18.56. About 418,902 shares traded. The Buckle, Inc. (NYSE:BKE) has risen 71.75% since December 9, 2017 and is uptrending. It has outperformed by 56.13% the S&P500. Some Historical BKE News: 17/05/2018 – Analysis: Positioning to Benefit within Apogee Enterprises, ArcBest, Buckle, Career Education, Abercrombie & Fitch, and Education Realty Trust — Research Highlights Growth, Revenue, and Consolidated Results; 15/05/2018 – DEEP ECO: Buckle May Benefit, Industry Sales Rise This Quarter; 10/05/2018 – Buckle’s First-quarter Same-store Sales Decline Less Than Expected, Net Sales Miss — MarketWatch; 24/05/2018 – Buckle Short-Interest Ratio Rises 25% to 31 Days; 16/03/2018 – Buckle Inc 4Q EPS 87c; 09/05/2018 – Buckle Short-Interest Ratio Rises 68% to 25 Days; 25/05/2018 – Buckle Inc 1Q EPS 38c; 08/03/2018 – BUCKLE INC BKE.N FEBRUARY SALES ROSE 2 PCT TO $64 MLN; 12/04/2018 – BUCKLE INC – COMPARABLE STORE NET SALES, FOR 5-WEEK PERIOD ENDED APRIL 7, 2018 DECREASED 1.1 PERCENT; 12/04/2018 – The Buckle, Inc. Reports March 2018 Net Sales

Jpmorgan Chase & Company increased Chemocentryx Inc (CCXI) stake by 190.64% reported in 2018Q2 SEC filing. Jpmorgan Chase & Company acquired 129,369 shares as Chemocentryx Inc (CCXI)’s stock declined 9.17%. The Jpmorgan Chase & Company holds 197,230 shares with $2.60 million value, up from 67,861 last quarter. Chemocentryx Inc now has $497.68 million valuation. The stock decreased 3.62% or $0.37 during the last trading session, reaching $9.85. About 213,959 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since December 9, 2017 and is uptrending. It has outperformed by 35.68% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: which released: “ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference – Nasdaq” on November 29, 2018, also with their article: “New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US — Consolidated Revenues, Company Growth, and Expectations for 2018 – GlobeNewswire” published on November 27, 2018, published: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” on September 28, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: and their article: “ChemoCentryx launches $75M stock offering – Seeking Alpha” published on September 26, 2018 as well as‘s news article titled: “ChemoCentryx Announces Proposed Public Offering of Common Stock – GlobeNewswire” with publication date: September 26, 2018.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. ChemoCentryx had 4 analyst reports since June 28, 2018 according to SRatingsIntel. Canaccord Genuity maintained ChemoCentryx, Inc. (NASDAQ:CCXI) rating on Monday, November 12. Canaccord Genuity has “Buy” rating and $20 target. The company was downgraded on Tuesday, August 14 by JP Morgan.

Jpmorgan Chase & Company decreased Hill Rom Hldgs Inc (NYSE:HRC) stake by 28,235 shares to 342,697 valued at $29.93 million in 2018Q2. It also reduced Perkinelmer Inc (NYSE:PKI) stake by 10,808 shares and now owns 176,027 shares. Union Pac Corp (NYSE:UNP) was reduced too.

Investors sentiment decreased to 0.98 in Q2 2018. Its down 0.61, from 1.59 in 2018Q1. It dived, as 11 investors sold CCXI shares while 28 reduced holdings. 28 funds opened positions while 34 raised stakes. 26.37 million shares or 8.85% more from 24.22 million shares in 2018Q1 were reported. Piedmont Inv Advsr Limited Liability Corp has 381 shares for 0% of their portfolio. Royal Retail Bank Of Canada accumulated 12 shares. Citadel Ltd Liability Corporation reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Sei Investments reported 0% stake. Retail Bank Of Montreal Can holds 0% or 104,104 shares in its portfolio. Jpmorgan Chase And accumulated 197,230 shares. Franklin Res invested in 0.01% or 1.52 million shares. Ameritas Invest Ptnrs has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Strs Ohio holds 0% or 60,200 shares. Tiaa Cref Mngmt reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). 414,029 are owned by Baker Bros Advisors L P. Winch Advisory Limited Liability Corp owns 400 shares. Panagora Asset Mgmt reported 0.02% in ChemoCentryx, Inc. (NASDAQ:CCXI). Trexquant Inv Ltd Partnership owns 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 17,056 shares. Legal & General Gp Public Limited Co owns 3,021 shares.

Since June 26, 2018, it had 0 insider buys, and 7 insider sales for $88.11 million activity. 25,179 shares were sold by Cappel Markus J., worth $344,201 on Wednesday, June 27. 99,507 shares were sold by KANAYA SUSAN M, worth $1.34 million on Tuesday, June 26. Another trade for 7.34 million shares valued at $85.85M was made by GLAXOSMITHKLINE PLC on Tuesday, October 16. $86,554 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Schall Thomas J..

Investors sentiment increased to 1.73 in 2018 Q2. Its up 0.48, from 1.25 in 2018Q1. It is positive, as 22 investors sold BKE shares while 45 reduced holdings. 34 funds opened positions while 50 raised stakes. 32.89 million shares or 2.75% more from 32.00 million shares in 2018Q1 were reported. Manufacturers Life The owns 22,285 shares or 0% of their US portfolio. Ny State Common Retirement Fund has 167,202 shares. Rhumbline Advisers holds 0.01% or 100,133 shares in its portfolio. Quinn Opportunity Prtnrs Limited Company holds 0.03% of its portfolio in The Buckle, Inc. (NYSE:BKE) for 10,733 shares. Horizon Kinetics Lc holds 0.01% or 15,228 shares in its portfolio. Fmr Limited Company reported 7.36 million shares or 0.02% of all its holdings. 96,787 are held by California Employees Retirement System. Employees Retirement Association Of Colorado holds 4,261 shares or 0% of its portfolio. Deutsche Fincl Bank Ag holds 58,206 shares or 0% of its portfolio. Wellington Management Gru Llp holds 167,335 shares. Lsv Asset holds 94,100 shares. Texas Permanent School Fund has 0.01% invested in The Buckle, Inc. (NYSE:BKE). Arizona State Retirement accumulated 41,387 shares. Ameritas Invest owns 19,762 shares or 0.03% of their US portfolio. Blackrock has invested 0% in The Buckle, Inc. (NYSE:BKE).

More notable recent The Buckle, Inc. (NYSE:BKE) news were published by: which released: “2 Retail Stocks Getting Walloped After Earnings – Schaeffers Research” on November 27, 2018, also with their article: “5 Stocks Moving In Monday’s After-Hours Session – Benzinga” published on November 26, 2018, published: “7 Stocks To Watch For November 27, 2018 – Benzinga” on November 27, 2018. More interesting news about The Buckle, Inc. (NYSE:BKE) were released by: and their article: “32 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” published on November 27, 2018 as well as‘s news article titled: “Stocks To Watch: Favorable Trade Winds? – Seeking Alpha” with publication date: December 01, 2018.

Since June 12, 2018, it had 2 insider purchases, and 3 selling transactions for $135,157 activity. 20,000 shares were sold by RHOADS KAREN B, worth $569,500. FAIRFIELD BILL L had bought 200 shares worth $3,711. HUSS MICHAEL E sold 1,688 shares worth $38,197. $12,902 worth of The Buckle, Inc. (NYSE:BKE) shares were sold by HARBOLS ROBERT J. On Thursday, September 13 APPLEGATE DIANE L sold $90,008 worth of The Buckle, Inc. (NYSE:BKE) or 4,000 shares.

Analysts await The Buckle, Inc. (NYSE:BKE) to report earnings on March, 15. They expect $0.77 earnings per share, down 11.49% or $0.10 from last year’s $0.87 per share. BKE’s profit will be $37.23M for 6.03 P/E if the $0.77 EPS becomes a reality. After $0.42 actual earnings per share reported by The Buckle, Inc. for the previous quarter, Wall Street now forecasts 83.33% EPS growth.

Contrarius Investment Management Ltd increased Penney J C Inc (NYSE:JCP) stake by 10.79 million shares to 14.63M valued at $34.23M in 2018Q2. It also upped Brinker Intl Inc (NYSE:EAT) stake by 423,705 shares and now owns 1.12M shares. Express Inc (NYSE:EXPR) was raised too.

The Buckle, Inc. (NYSE:BKE) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *